Savings & Support

On this page

Lilly Support Services^™ for Inluriyo^®

Enroll Your Eligible Patients in Lilly Support Services for Inluriyo

Support tailored to an eligible patient's Inluriyo treatment journey.

If you have questions regarding any of these support services, call 1-800-LillyRx (1-800-545-5979).

Inluriyo Savings Card

Begin your patient's enrollment journey for a savings card.

Governmental beneficiaries excluded, terms and conditions apply.

Ongoing Support

Lilly Support Services^™ can help eligible Inluriyo patients by:

Connecting them to relevant resources based on questions or needs

Reiterating treatment information when taking Inluriyo^†

^†Lilly Support Services^™ for Inluriyo does not replace a trained healthcare provider; when medical questions arise, your patients will always be directed back to your office.

Prior Authorization (PA) & Appeals Support^*

Prior Authorization (PA)

Lilly Support Services can inform the HCP of the plan-specific prior authorization request process, including where to send the request and the estimated turnaround time
Lilly Support Services communicates regularly with the payer to track progress and inform the HCP of the final result

Appeals Support

Lilly Support Services offers appeals support during the payer approval process by providing information and forms

Benefits Investigation^*

Lilly Support Services^™ can research patient-specific benefits to determine coverage options and research precertification requirements if needed.
Lilly Support Services^™ can relay results to the patient and HCP and give instructions on any necessary next steps (eg, obtaining a prior authorization).

Interim Access

Interim Access Program for Inluriyo^®

The Inluriyo Interim Access Program allows insured, eligible patients who have been prescribed Inluriyo for the first time and are experiencing a delay in their insurance coverage determination to receive a 14-day supply of Inluriyo at no charge. See terms and conditions below.^*

Enrollment in this program must be completed by you or your office on the patient's behalf.

There is no patient self-enrollment pathway.

*TERMS AND CONDITIONS: The Inluriyo Interim Access Program (or “Program”) provides a 14-day supply of Inluriyo at no charge for eligible, insured patients who are: 1) prescribed Inluriyo for the first time, 2) experiencing a minimum 5-business-day delay in insurance coverage determination, 3) prescribed Inluriyo for an FDA-approved indication or an indication medically supported by CMS-recognized compendia, 4) enrolled in Lilly Support Services™, and 5) residents of the United States or Puerto Rico. May not be combined with any other offer. Not available to patients whose insurers have made a final determination to deny the patient coverage for Inluriyo. If a denial is received after the initial 5 business days have passed and appeal rights are being pursued, or if there is a persistent coverage delay, the patient, under appropriate circumstances, may be eligible for up to 3 additional 14-day supplies of Inluriyo. Product provided through the Program is only available through the Program noncommercial specialty pharmacy. Product is provided free of charge and may not be sold, bartered, or returned for credit. Reimbursement cannot be sought from any third party for product provided under the Program. Patients enrolled in Medicare Part D are prohibited from counting any portion of the cost of the product provided under the Program toward true out-of-pocket (“TrOOP”) costs for prescription drug calculations. No purchase contingency or other obligation accompanies Program participation. This Program is not health insurance and does not guarantee coverage. Lilly reserves the right to change or end the Program at any time. Benefits under the Program are not transferable.

CMS=Centers for Medicare & Medicaid Services; FDA=US Food and Drug Administration.

Easily Enroll Your Eligible Patients in Lilly Support Services™ for Inluriyo®

One enrollment connects your patient to all applicable support programs. Call 1-800-LillyRx (1-800-545-5979), Mon–Fri, 8 am–10 pm ET.

Explore more information on Lilly Support Services™ for Verzenio.

Access Resources

Ordering Inluriyo

Inluriyo can be purchased from authorized distributors and is available through:

Contracted specialty pharmacies^§

Hospital and health system practices

In-office dispensing (IOD) practices

^§Eligible pharmacies can purchase Inluriyo through authorized distribution partners. A list of authorized distributors can be found at trade.lilly.com.

Access, Distribution, and
Reimbursement Guide

Navigate the reimbursement landscape with this comprehensive reference guide.

Coverage Authorization
Appeals Letter

For when an initial claim or coverage authorization request is denied by the payer.

Letter of Medical
Necessity (LMN)

Many health plans require an LMN to accompany a coverage authorization appeals letter.

EHR Resources — Electronic Order Sets

Easy-to-use, step-by-step downloadable instructions to develop Inluriyo electronic order sets in your EHR system.

System not listed? Download the Treatment Plan Guide →

Trademarks are the property of their respective owners.

Inluriyo Savings Card

Alternate pathway to savings card enrollment, download an activated savings card on behalf of your patient.

Eligible, commercially insured patients may pay

a month*

Government beneficiaries excluded, terms and conditions apply

By enrolling in and using the Inluriyo Savings Card Program (“Program”) and using the Inluriyo Savings Card (“Card”), you attest that you meet the eligibility criteria, and you agree to comply with the terms and conditions described below:

Card Eligibility:

You have been prescribed Inluriyo^® (imlunestrant) for an approved use consistent with FDA approved product labeling;
You are enrolled in a commercial drug insurance plan and have coverage for Inluriyo;
You are not enrolled in any state, federal, or government funded healthcare program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE^®/CHAMPUS, or any state prescription drug assistance program;
You are a resident of the United States or Puerto Rico; and
You are 18 years of age or older.

Card Terms and Conditions

For patients with commercial drug insurance coverage for Inluriyo: You must have commercial drug insurance that covers Inluriyo and a prescription for an approved use consistent with FDA-approved product labeling to pay as little as $0 for a 1-month prescription fill of Inluriyo. Month is defined as 28 days. Card savings are subject to a maximum monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges and separate maximum annual savings of up to $10,600 per calendar year. Card may be used for a maximum of up to 14 prescription fills per calendar year. Except where prohibited by applicable state law, Card monthly and annual savings are reduced if Lilly identifies that you are enrolled in a plan or program, sometimes called a maximizer plan, that adjusts your cost sharing amount to be equal to or include some portion of the savings provided by the Card and attempts to prevent the savings from this Card from being applied to your out-of-pocket costs, including but not limited to copayments, coinsurances, and deductibles (“Maximizer”). If the Program identifies you are enrolled in a Maximizer, Card savings are reduced to a maximum monthly savings of up to $25 and a separate maximum annual savings of up to $350 per calendar year. If you have reason to believe that the Program erroneously identified enrollment in a Maximizer, please call the Inluriyo Savings Card Program at 1-844-583-3550. Subject to Lilly USA, LLC's (“Lilly”) right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly's sole discretion, without notice, and for any reason. Card expires and savings end on 12/31/2026.

Additional Program Terms and Conditions

If you have an insurance plan that is participating in an alternate funding program (“AFP”) that requires you to apply to the Inluriyo Savings Card Program or otherwise pursue specialty drug prescription coverage through an alternate funding vendor as a condition of, requirement for, or prerequisite to coverage of Inluriyo, you are not eligible for and are prohibited from using the Inluriyo Savings Card Program. AFPs include programs where coverage, reimbursement, or patient out of pocket costs for a product in some way vary based on the availability of a manufacturer co-pay program. AFPs may modify, delay, deny, restrict, or withhold insurance benefits or coverage from patients, or exclude Lilly products from coverage contingent upon a member's use of Inluriyo Savings Card Program. You agree to inform the Inluriyo Savings Card Program if you are or become a member of such an alternative funding program. You are responsible for any applicable taxes, fees, and any amount that exceeds the monthly or annual maximum Card savings. Monthly and annual maximum savings are set at Lilly's sole and absolute discretion and may be changed with or without notice at any time for any reason. At its sole discretion and with or without notice, Lilly may reduce, eliminate, or otherwise modify the Card savings for any reason, including but not limited to if your commercial drug insurance plan imposes additional requirements which limits or prevents you from receiving coverage for Inluriyo, only allows partial coverage for Inluriyo, removes coverage for Inluriyo and requires you to utilize the Card, does not provide a material level of financial assistance for the cost of Inluriyo, or does not apply Card payments to satisfy your co-payment, deductible, or coinsurance for Inluriyo. Card savings are not valid for: Massachusetts residents if an AB-rated generic equivalent is available; California residents if an FDA-approved therapeutic equivalent is available. You must meet the Card eligibility criteria, terms and conditions every time you use the Card. If at any time you begin receiving drug coverage under any state, federal, or government funded healthcare program, you understand that you will no longer be eligible for the Inluriyo Savings Card and agree to call the Inluriyo Savings Card Program at 1-844-583-3550 to stop participation. Card activation is required. You may not seek reimbursement from your health insurance, any third party, or any health savings, flexible spending, or other healthcare reimbursement accounts, for any amount of the savings received through the Card. By utilizing the Card, you agree that if you are required to do so under the terms of your insurance coverage for this prescription or are otherwise required to do so by law, you will notify your Insurance Carrier of your redemption of the Card. Card savings cannot be combined or utilized with any other program, discount, discount card, cash discount card, coupon, incentive, or similar offer involving Inluriyo. You agree that this Card savings is intended solely for the benefit of you, the patient, and that the Card benefits are non-transferable. It is prohibited for any person to sell, purchase, or trade; or to offer to sell, purchase, or trade, or to counterfeit the Card.THIS CARD IS NOT INSURANCE. Lilly has the sole right to interpret and apply Card eligibility criteria, and terms and conditions. Card eligibility, and terms and conditions may be terminated, rescinded, revoked, or amended by Lilly at any time without notice and for any reason. Lilly's sole discretion to terminate, rescind, revoke, or amend Card eligibility and/or Card terms and conditions includes the right to terminate any individual Card if Lilly determines, in its sole discretion, that a patient does not satisfy the Card's eligibility criteria or is using or has attempted to use the Card inconsistently with these terms and conditions. Eligibility criteria, and terms and conditions for the Inluriyo Savings Card Program may change from time to time; the most current version can be found at https://www.inluriyo.lilly.com/savings-support#terms-and-conditions. You may be required to obtain a new Card, including if any Card terms and conditions have been terminated, rescinded, revoked, or amended by Lilly. Card void where prohibited by law. Subject to Lilly's right to terminate, rescind, revoke or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly's sole discretion, without notice, and for any reason. Card expires and savings end on 12/31/2026.

HCPs can download the Savings Card to deliver to eligible, commercially insured patients with coverage for Inluriyo. Governmental beneficiaries excluded, terms and conditions apply.^*

Contact us

Lilly Support Services

1-800-LillyRx

(1-800-545-5979)

Mon – Fri, 8 am – 10 pm ET

Savings Card Program

1-844-583-3550

For Savings Card questions and troubleshooting

CMAT-31283 09/2026

Indications

Inluriyo^® in combination with Verzenio^® is indicated:

for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy^1,2

Inluriyo monotherapy is indicated:

for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy¹

IMPORTANT SAFETY INFORMATION FOR INLURIYO® (imlunestrant) AS MONOTHERAPY IN COMBINATION WITH VERZENIO® (abemaciclib)

Diarrhea: Severe diarrhea associated with dehydration and infection occurred in patients treated with Verzenio. Instruct patients at the first sign of loose stools to initiate antidiarrheal therapy, increase oral fluids, and notify their healthcare provider. In EMBER-3, diarrhea occurred in 86% of patients who received Inluriyo in combination with Verzenio; Grade 3 or 4 diarrhea occurred in 9%. Follow specific dose modification and management instructions located in the Prescribing Information for each drug.

Neutropenia: Neutropenia, including febrile neutropenia and fatal neutropenic sepsis, occurred in patients treated with Verzenio. In EMBER-3, neutrophil count decreased in 86% of patients who received Inluriyo in combination with Verzenio; Grade 3 or 4 decreases occurred in 21%. Monitor complete blood counts prior to the start of Verzenio therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated. Follow specific dose modification and management instructions located in the Prescribing Information for each drug.

Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, or fatal interstitial lung disease (ILD) or pneumonitis can occur in patients treated with Verzenio and other CDK4/6 inhibitors. In EMBER-3, ILD or pneumonitis occurred in 2.9% of patients who received Inluriyo in combination with Verzenio. Monitor for clinical symptoms or radiological changes indicative of ILD/pneumonitis. Permanently discontinue Verzenio in all patients with Grade 3 or 4 ILD or pneumonitis. Follow specific dose modification and management instructions located in the Prescribing Information for each drug.

Hepatotoxicity: Increases in serum transaminase levels have been observed. Perform liver function tests (LFTs) before initiating treatment with Verzenio. Monitor LFTs every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated with Verzenio. Monitor ALT and AST during treatment with Inluriyo as clinically indicated. In EMBER-3, ALT increase occurred in 33% for all grades (Grade 3 or 4: 5%) and AST increase occurred in 36% for all grades (Grade 3 or 4: 2.5%) of patients who received Inluriyo in combination with Verzenio. Follow specific dose modification and management instructions located in the Prescribing Information for each drug.

Venous Thromboembolism: Deaths due to venous thromboembolism have been reported in patients treated with Verzenio. In EMBER-3, venous thromboembolic events occurred in 4.8% of patients who received Inluriyo in combination with Verzenio. Monitor patients for signs and symptoms of thrombosis and pulmonary embolism and treat as medically appropriate. Follow specific dose modification and management instructions located in the Prescribing Information for each drug.

Embryo-Fetal Toxicity: Inluriyo and Verzenio can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Verify pregnancy status in females of reproductive potential prior to initiating treatment. Advise females of reproductive potential to use effective contraception during treatment with Inluriyo in combination with Verzenio and for 3 weeks after the last dose of Verzenio or 1 week after the last dose of Inluriyo, whichever is longer. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 1 week after the last dose of Inluriyo.

For Inluriyo monotherapy, advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with Inluriyo and for 1 week after the last dose.

Increased Serum Creatinine Without Affecting Renal Function: Verzenio can increase serum creatinine. These increases were not associated with changes in glomerular function. In EMBER-3, creatinine increase occurred in 36% for all grades (Grade 3 or 4: 1.1%) of patients who received Inluriyo in combination with Verzenio. During Verzenio treatment, use alternative measures that are not based on serum creatinine to assess renal function, such as BUN, cystatin C, or calculated GFR.

Serious and Fatal Adverse Reactions for Inluriyo in Combination with Verzenio: Serious adverse reactions occurred in 21% of patients who received Inluriyo in combination with Verzenio. Serious adverse reactions in >1% of patients who received Inluriyo in combination with Verzenio included pneumonia (2.4%), abdominal pain, and renal failure (each 1.4%). Fatal adverse reactions occurred in 3.8% of patients who received Inluriyo in combination with Verzenio, including pneumonia (1.4%), myocardial infarction, interstitial lung disease, and sepsis (0.5% each).

Most Common Adverse Reactions for Inluriyo in Combination with Verzenio: The most common (≥10%) adverse reactions with Inluriyo in combination with Verzenio, including laboratory abnormalities, were decreased neutrophils, diarrhea, decreased hemoglobin, decreased lymphocytes, nausea, decreased platelets, fatigue, increased triglycerides, infections, increased AST, increased creatinine, increased ALT, vomiting, musculoskeletal pain, abdominal pain, decreased appetite, increased cholesterol, rash, cough, headache, and decreased weight.

Serious and Fatal Adverse Reactions for Inluriyo Monotherapy: Serious adverse reactions occurred in 10% of patients who received Inluriyo. Serious adverse reactions in >1% of patients included pleural effusion (1.2%). Fatal adverse reactions occurred in 1.8% of patients who received Inluriyo, including cardiac arrest, acute myocardial infarction, right ventricular failure, hypovolemic shock, and upper gastrointestinal hemorrhage (each 0.3%).

Most Common Adverse Reactions for Inluriyo Monotherapy: The most common (≥10%) adverse reactions with Inluriyo monotherapy, including laboratory abnormalities were decreased hemoglobin, musculoskeletal pain, decreased calcium, decreased neutrophils, increased AST, fatigue, diarrhea, increased ALT, increased triglycerides, nausea, decreased platelets, constipation, increased cholesterol, and abdominal pain.

Drug Interactions – Inluriyo:

Avoid concomitant use with strong CYP3A inhibitors. If concomitant use cannot be avoided, decrease the Inluriyo dosage. Avoid concomitant use with strong CYP3A inducers. If concomitant use cannot be avoided, increase the Inluriyo dosage. See Prescribing Information for recommended dosage modifications.
Imlunestrant inhibits both P-gp and BCRP. Avoid concomitant use unless otherwise recommended in the Prescribing Information for P-gp or BCRP substrates where minimal concentration changes may lead to serious adverse reactions.

Drug Interactions – Verzenio:

CYP3A Inhibitors: Avoid concomitant use of ketoconazole. Reduce the Verzenio dose with concomitant use of other strong and moderate CYP3A inhibitors. Monitor for adverse reactions and follow the specific dose modification instructions located in the Prescribing Information. Patients should avoid grapefruit products.
CYP3A Inducers: Avoid concomitant use of strong and moderate CYP3A inducers and consider alternative agents.

Lactation: Because of the potential for serious adverse reactions in the breastfed child, advise lactating women to not breastfeed during treatment with Inluriyo in combination with Verzenio and for 3 weeks after the last dose of Verzenio or 1 week after the last dose of Inluriyo, whichever is longer.

For Inluriyo monotherapy, advise lactating women to not breastfeed during treatment with Inluriyo and for 1 week after the last dose.

Hepatic Impairment: With Inluriyo, reduce the dose in patients with moderate or severe hepatic impairment. The recommended dosage for patients with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment is 200 mg once daily. No dosage modification is recommended for patients with mild hepatic impairment (Child-Pugh A).

With Verzenio, reduce the dosing frequency to once daily in patients with severe hepatic impairment (Child-Pugh C). No dosage adjustments are necessary in patients with mild or moderate hepatic impairment (Child-Pugh A or B).

Infertility: Inluriyo may impair fertility in females and males of reproductive potential.

Verzenio may impair fertility in males of reproductive potential.

Inluriyo (imlunestrant) is available as 200 mg tablets.

Verzenio (abemaciclib) is available as 50 mg, 100 mg, 150 mg, and 200 mg tablets.

Please click to access Prescribing Information Inluriyo and Verzenio.

IN VZ HCP ISI Combo+Mono APPR

Inluriyo^® and Verzenio^® are registered trademarks and Lilly Support Services^™ is a trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

Lilly Support Services™ helps your patients start treatment quickly and provides resources to support their journey*

Lilly Support Services™ for Inluriyo®